Clinical trial
High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
NCT00034242 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00034242 |
|---|---|
| Title | High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration |
| Official title | The Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With Cerebellar Degeneration: A Double Blind, Placebo Controlled Trial |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Spinocerebellar Degenerations |
| Intervention type | Drug |
| Interventions | high-dose intravenous immunoglobulin (IVIG) |
| Enrollment | 20 |
| Start date | Apr 1, 2002 |
| Completion | Feb 1, 2004 |
| First posted | Apr 24, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: